Investment Rating - The report initiates coverage with a "Buy" rating for Jiangzhong Pharmaceutical, indicating a potential upside of 36% based on a target market value of 214 billion yuan compared to the current market value of 157 billion yuan [7][8]. Core Insights - Jiangzhong Pharmaceutical is positioned as a leader in gastrointestinal health, with a diversified business model encompassing OTC, prescription drugs, and health consumer products. The company has successfully built a strong brand presence with its well-known trademarks "Jiangzhong" and "Chuyuan" [5][16]. - The company has a robust product portfolio, including major products in the OTC market such as the 1 billion yuan "Jiangzhong Digestive Tablets" and the 500 million yuan "Lactobacillus Tablets" [7][36]. - The financial outlook is positive, with projected net profits for 2025-2027 expected to grow at compound annual growth rates of 8.3%, 10.0%, and 11.9%, respectively [6][8]. Summary by Sections Company Overview - Jiangzhong Pharmaceutical was established in 1969 and became publicly listed in 1998. The company has undergone significant restructuring and acquisitions, including the purchase of Jisheng Pharmaceutical and Sanghai Pharmaceutical, to enhance its market position [5][16]. - The company has a stable shareholding structure, with China Resources Group as the largest shareholder, which strengthens its operational capabilities and risk management [18][19]. Financial Data and Profit Forecast - The total revenue for 2024 is projected at 4.435 billion yuan, with a slight decline expected in 2025 before a recovery in subsequent years, reaching 5.089 billion yuan by 2027 [6]. - The gross profit margin is expected to remain stable around 65%, with the OTC segment showing a slight increase in profitability due to product mix optimization [26]. Investment Highlights - The company is focusing on expanding its OTC market presence by leveraging its strong brand and developing new product categories. The gastrointestinal product line is expected to maintain stable growth, while the health consumer products segment is anticipated to benefit from demographic trends such as aging populations [7][32]. - Jiangzhong Pharmaceutical's prescription drug segment is also expected to grow as the company continues to enhance its product offerings through acquisitions and strategic partnerships [7][32]. Market Position and Competitive Landscape - The company has maintained a leading market share in the OTC segment, particularly with its flagship product, the Jiangzhong Digestive Tablets, which ranked second in sales among digestive system medications in urban pharmacies [38][44]. - The competitive landscape for gastrointestinal products is fragmented, but Jiangzhong Pharmaceutical's brand strength allows it to maintain a dominant position [42][44].

Core Insights - Jiangzhong Pharmaceutical achieved a revenue of 4.435 billion yuan in 2024, a year-on-year decrease of 2.59%, while the net profit attributable to shareholders was 788 million yuan, an increase of 9.67% [1] - The OTC segment showed strong demand with a revenue of 3.266 billion yuan, reflecting a year-on-year growth of 7.07% [1] OTC Segment Performance - Key products in the gastrointestinal field, such as the core product "Gastrointestinal Digestive Tablets," saw a double-digit revenue growth, with sales reaching 169 million boxes, up by 10.91% year-on-year [1] - In the throat and cough segment, core products like "Compound Fresh Bamboo Liquid" and "Compound Grass Coral Tablets" contributed to double-digit growth, with sales of "Compound Grass Coral Tablets" reaching 37 million boxes, up by 4.05% year-on-year [1] - The nutritional supplement segment saw a revenue of over 200 million yuan, with sales of "Multivitamin Tablets" at 12 million boxes, down by 10.30% year-on-year [1] Health Business and Prescription Drug Segment - The health segment reported a revenue of 345 million yuan, a significant year-on-year decline of 47.30%, attributed to intensified industry competition and restructuring efforts [2] - The prescription drug segment generated a revenue of 793 million yuan, down by 3.50% year-on-year, with the decline narrowing due to the consolidation of traditional Chinese medicine pieces [2] Profitability and Cost Management - The company's gross margin was 63.52%, a decrease of 0.51 percentage points year-on-year, with the OTC segment having the highest gross margin at 72.74% [3] - The sales expense ratio improved to 33.70%, down by 2.33 percentage points year-on-year, while the net profit margin increased to 17.77%, up by 1.99 percentage points year-on-year [3] Dividend Policy and Future Outlook - The company announced a cash dividend of 7 yuan per 10 shares, resulting in a cash dividend ratio of 55.86%, with an overall annual dividend ratio reaching 95.77% [3] - The company aims for double-digit growth in revenue and profit by 2025, supported by a dual-driven strategy of "internal growth + external expansion" [3][4]

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company achieved a revenue of 4.435 billion RMB in 2024, a decrease of 3% year-on-year, while the net profit attributable to shareholders increased by 10% year-on-year to 788 million RMB, indicating that the performance met expectations [1] - The OTC segment showed resilience with a revenue of 3.27 billion RMB in 2024, reflecting a 7% year-on-year growth, driven by strong performance in specific products [2] - The company plans to distribute a cash dividend of 755 million RMB, representing 95.77% of the net profit attributable to shareholders for 2024, highlighting its commitment to shareholder returns [3] - The company has raised its operational targets for 2025, indicating confidence in achieving a compound annual growth rate of at least 12% for net profit from 2025 to 2027 [4] - The target price for the company is set at 28.53 RMB, based on a 20x PE ratio for 2025, reflecting a positive outlook for future earnings growth [5] Summary by Sections Financial Performance - In 2024, the company reported a revenue of 4.435 billion RMB, with a net profit of 788 million RMB, and a non-recurring net profit of 749 million RMB, showing a year-on-year increase of 10% and 6% respectively [1] - The fourth quarter of 2024 saw a revenue of 1.464 billion RMB, marking a 17% year-on-year increase, and a net profit of 154 million RMB, up 30% year-on-year [1] Segment Analysis - The OTC segment's revenue for 2024 was 3.27 billion RMB, growing by 7% year-on-year, with significant contributions from gastrointestinal products and other key items [2] - The health consumer products segment faced a decline of 47% year-on-year, attributed to increased competition and restructuring efforts, but is expected to recover significantly in 2025 [2] - The prescription drug segment reported a revenue of 790 million RMB, down 3% year-on-year, but is anticipated to stabilize and grow in the medium to long term [2] Dividend Policy - The company plans to maintain a high dividend payout, with a cash dividend of 755 million RMB for 2024, reflecting a strong commitment to returning value to shareholders [3] Future Outlook - The company has set ambitious targets for 2025-2027, including a minimum return on capital of 15.42% and a compound annual growth rate for net profit of at least 12% [4] - The earnings forecast for 2025-2027 predicts net profits of 897 million RMB, 1.015 billion RMB, and 1.145 billion RMB respectively, indicating a growth trajectory of 14%, 13%, and 13% year-on-year [5]